EPISODE · Jun 2, 2025 · 14 MIN
ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate
from BiotechTV - News · host BiotechTV
CEO David Chang\ describes the data and explains why he believes the company's "Dagger" platform makes a difference. Plus, an update on Allogene's 1L consolidation trial in LBCL, and his thoughts on cell therapy for autoimmune diseases.
What this episode covers
CEO David Chang\ describes the data and explains why he believes the company's "Dagger" platform makes a difference. Plus, an update on Allogene's 1L consolidation trial in LBCL, and his thoughts on cell therapy for autoimmune diseases.
NOW PLAYING
ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m